Lilly in Deal With ImmuNext to Develop Autoimmune Disease Treatments

Eli Lilly & Co. (LLY) has reached a deal with ImmuNext Inc. to study and develop a new treatment for autoimmune diseases.

Lilly said Tuesday the three-year research agreement with New Hampshire-based ImmuNext would target medicines that would regulate immune cell metabolism. Under the agreement Indianapolis-based Lilly will pay ImmuNext $40 million up front and ImmuNext would be eligible for up to roughly $565 million on certain milestones as well as royalties on product sales.

The agreement also gives Lilly world-wide rights to develop and commercialize the potential treatment.

With the transaction, Lilly affirmed its full-year adjusted per-share earnings guidance.

https://www.marketscreener.com/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-and-Lilly-Enters-Deal-With-ImmuNext-to-Develop-Autoimmune-Disease-Treatments-28242678/